BioMedNewsBreaks – Genesis Unicorn Capital Corp. (NASDAQ: GENQU) Announces Closing of IPO, Full Exercise of Over-Allotment Option

Genesis Unicorn Capital (NASDAQ: GENQU) recently announced the closing of its initial public offering of 7,500,000 units, each at $10.00. Each unit consists of one share of Class A common stock and one warrant entitling the holder to purchase one share of Class A common stock at a price of $11.50 per share. The underwriters fully exercised the over-allotment option for an additional 1,125,000 units on Feb. 15, 2022, which closed at the time of the closing of the offering. As a result, Genesis Unicorn Capital secured aggregate gross proceeds of $86,250,000 from the offering and over-allotment. The units began trading on the Nasdaq Global Market on Feb. 15, 2022, under the ticker symbol GENQU. Once the securities comprising the units begin separate trading, the shares of Class A common stock and warrants are expected to be listed on the Nasdaq under the symbols GENQ and GENQW, respectively. EF Hutton, division of Benchmark Investments LLC, served as sole book-running manager for the offering. Becker & Poliakoff LLP served as legal counsel to the company. Hogan Lovells US LLP served as legal counsel to EF Hutton.

To view the full press release, visit https://ibn.fm/vBPRd

About Genesis Unicorn Capital Corp.

Genesis Unicorn Capital is a newly organized blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company has not selected any specific business combination target and has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. While the company may pursue an initial business combination target in any business or industry, it intends to focus its search on the intersection of the health care and technology industries, specifically within the biotechnology and pharmaceutical sectors.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork